Find Osimertinib Mesylate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

API REF. PRICE (USD/KG)

MARKET PLACE

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1421373-66-1, Azd-9291 mesylate, Azd9291 mesylate, Azd-9291 (mesylate), Mereletinib mesylate, Tagrisso
Molecular Formula
C29H37N7O5S
Molecular Weight
595.7  g/mol
InChI Key
FUKSNUHSJBTCFJ-UHFFFAOYSA-N
FDA UNII
RDL94R2A16

Osimertinib Mesylate
Osimertinib Mesylate is the mesylate salt form of osimertinib, a third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.
1 2D Structure

Osimertinib Mesylate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide;methanesulfonic acid
2.1.2 InChI
InChI=1S/C28H33N7O2.CH4O3S/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24;1-5(2,3)4/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32);1H3,(H,2,3,4)
2.1.3 InChI Key
FUKSNUHSJBTCFJ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O
2.2 Other Identifiers
2.2.1 UNII
RDL94R2A16
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Azd-9291

2. Azd-9291 Mesylate

3. Azd9291

4. Azd9291 Mesylate

5. Mereletinib

6. Mereletinib Mesilate

7. Mereletinib Mesylate

8. N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide

9. N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide Methanesulfonate (1:1)

10. Osimertinib

11. Osimertinib Mesilate

12. Tagrisso

2.3.2 Depositor-Supplied Synonyms

1. 1421373-66-1

2. Azd-9291 Mesylate

3. Azd9291 Mesylate

4. Azd-9291 (mesylate)

5. Mereletinib Mesylate

6. Tagrisso

7. Osimertinib Mesilate

8. Mereletinib Mesilate

9. Osimertinib Mesylate [usan]

10. Rdl94r2a16

11. N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide;methanesulfonic Acid

12. N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide Methanesulfonate

13. Osimertinib Mesilate (jan)

14. Osimertinib Mesylate (usan)

15. 2-propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, Methanesulfonate (1:1)

16. Osimertinib Mesilate [jan]

17. 2-propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-, Compd. With Methanesulfonate (1:2)

18. Unii-rdl94r2a16

19. Tagrisso (tn)

20. Osimertinib Monomesylate

21. Azd 9291 Mesylate

22. Osimertinib Methanesulfonate

23. Amy226

24. Chembl3545063

25. Schembl14661152

26. Chebi:90948

27. Osimertinib Mesylate [mi]

28. Dtxsid101027822

29. Bcp09934

30. Ex-a1577

31. Hy-15772a

32. Mfcd28137994

33. Osimertinib Mesilate [who-dd]

34. Akos026673944

35. Ds-9913

36. Sb22953

37. Ac-29022

38. Da-35303

39. Osimertinib Mesylate [orange Book]

40. Azd-9291 Mesylate (osimertinibmereletinib)

41. Ft-0699962

42. S5078

43. D10766

44. Q27162942

45. Azd9291 Ms Salt, Osimertinib Ms Salt; Mereletinib Ms Salt

46. N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide Methanesulfonate

47. N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide Methanesulfonate

2.3.3 Other Synonyms

1. Osimertinib

2.4 Create Date
2014-10-10
3 Chemical and Physical Properties
Molecular Weight 595.7 g/mol
Molecular Formula C29H37N7O5S
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count10
Rotatable Bond Count10
Exact Mass595.25768848 g/mol
Monoisotopic Mass595.25768848 g/mol
Topological Polar Surface Area150 Ų
Heavy Atom Count42
Formal Charge0
Complexity845
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

TAGRISSO as monotherapy is indicated for:

-the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations

- the first-line treatment of adult patients NSCLC with activating EGFR mutations.

- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

TAGRISSO as monotherapy is indicated for:

- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

- the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.

- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)


5.2 ATC Code

L01XE


API SUPPLIERS

read-more
read-more

01

Egis Pharmaceuticals PLC

Hungary

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Egis Pharmaceuticals

02

Fermion Oy

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Biotech Digital Meet
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothWith Fermion, start the journey of your innovative API.

Flag Finland
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
fermion

03

Faran Shimi Pharmaceutical

Iran

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Biotech Digital Meet
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFaran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.

Flag Iran
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Faran Shimi Pharmaceutical

04

Aarti Pharmalabs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Biotech Digital Meet
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Aarti Industries Company Banner

05

Shandong Loncom Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Biotech Digital Meet
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shandong Loncom Pharmaceutical company banner

06

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

07

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Biotech Digital Meet
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Biotech Digital Meet
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF arrow-down VMF Others AUDIT
blank

08

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Biotech Digital Meet
Not Confirmed
arrow

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Biotech Digital Meet
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

09

Alembic Pharmaceuticals Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Biotech Digital Meet
Not Confirmed
arrow

Alembic Pharmaceuticals Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Biotech Digital Meet
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC KDMF arrow-down VMF Others AUDIT
blank

10

ScinoPharm Taiwan, Ltd

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Biotech Digital Meet
Not Confirmed
arrow

ScinoPharm Taiwan, Ltd

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Biotech Digital Meet
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Biotech Digital Meet
Not Confirmed

02

Hetero Labs Ltd

India

USDMF

arrow
Biotech Digital Meet
Not Confirmed

02

Biotech Digital Meet
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 35581

Submission : 2021-02-04

Status : Active

Type : II

blank

03

Biotech Digital Meet
Not Confirmed

03

Biotech Digital Meet
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2019-05-06

Pay. Date : 2019-03-14

DMF Number : 32143

Submission : 2017-12-29

Status : Active

Type : II

blank

04

Scinopharm Taiwan Ltd

Taiwan

USDMF

arrow
Biotech Digital Meet
Not Confirmed
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-more

01

Biotech Digital Meet
Not Confirmed
arrow
arrow
Biotech Digital Meet
Not Confirmed

Osimertinib Mesylate IH

Date of Issue : 2022-06-17

Valid Till : 2025-07-02

Written Confirmation Number : WC-0082

Address of the Firm : API Division Kharakhadi, Plot No. 842-843, Kharakhadi, Padra Vadodara-391 450, G...

blank

02

Biotech Digital Meet
Not Confirmed
arrow
arrow
Biotech Digital Meet
Not Confirmed

Osimertinib Mesylate

Date of Issue : 2021-10-05

Valid Till : 2022-07-02

Written Confirmation Number : WC-0082A11

Address of the Firm : API Division Kharakhadi, Plot No. 842-843, Kharakhadi, Padra Vadodara-391 450, G...

blank

03

Biotech Digital Meet
Not Confirmed
arrow
arrow
Biotech Digital Meet
Not Confirmed

Osimertinib Mesylate IH

Date of Issue : 2022-09-02

Valid Till : 2025-05-05

Written Confirmation Number : WC-0349

Address of the Firm : MIs. MSN Laboratories Private Limited, Unit-II, sv. No, 50, Kardanur (Village), ...

blank

04

Natco Pharma

India
Biotech Digital Meet
Not Confirmed
arrow

Natco Pharma

India
arrow
Biotech Digital Meet
Not Confirmed

Osimertinib Mesylate IH

Date of Issue : 2019-10-07

Valid Till : 2022-06-12

Written Confirmation Number : WC-0372

Address of the Firm : S. No. 73/1A, 74/7B, 78/1B, 79/1, 2B 3 4B 5 6A, 6B, 7, 80/1,2 3,4, 84/1, 2, 3A, ...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

Biotech Digital Meet
Not Confirmed
arrow
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB

NDC Package Code : 54864-844

Start Marketing Date : 2015-11-13

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

Lonza AG

U.S.A
Biotech Digital Meet
Not Confirmed
arrow

Lonza AG

U.S.A
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

NDC Package Code : 49187-0835

Start Marketing Date : 2015-11-30

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

Biotech Digital Meet
Not Confirmed
arrow
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

NDC Package Code : 54893-0068

Start Marketing Date : 2017-12-29

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

04

Biotech Digital Meet
Not Confirmed
arrow
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

NDC Package Code : 65129-1451

Start Marketing Date : 2022-06-01

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

05

Biotech Digital Meet
Not Confirmed
arrow
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

NDC Package Code : 54245-1451

Start Marketing Date : 2022-06-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content

Osimertinib

About the Company : Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its produc...

Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its products under Egis’ brand names in 18 countries. In total, the company’s APIs & finished products reach 100 countries. Egis’ focus lies on treating diseases of cardiovascular & central nervous systems; however, it also provides modern treatment solutions in the fields of diabetology, dermatology & wound care. Our research and development activities focus on high-quality, value-added branded generic products. From 2023, Egis offers its CDMO & CMO services as well.
Egis Pharmaceuticals

02

Fermion Oy

Finland
arrow
Biotech Digital Meet
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothWith Fermion, start the journey of your innovative API.

Flag Finland
Digital Content Digital Content

Osimertinib

About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & F...

Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.
fermion

03

arrow
Biotech Digital Meet
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFaran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.

Flag Iran
Digital Content Digital Content

Osimertinib Mesylate

About the Company : Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutical Ingredients (APIs)...

Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutical Ingredients (APIs) and finished dosage forms. For the past three years, the company focused on extracting alkaloid opiates, controlled substances, and narcotics. The APIs are widely used by major pharmaceutical companies nationwide and exported to the Middle East. All production adheres to local GMP standards in an SOP-driven environment with modern systems and utilities, ensuring the highest quality and safety.
Faran Shimi Pharmaceutical

04

arrow
Biotech Digital Meet
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

Flag India
Digital Content Digital Content

Osimertinib

About the Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cyto...

Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cytotoxic & oncology products. It has 2 R&D centers & 3 cGMP plants successfully audited by the USFDA, EUGMP, EDQM, KFDA & COFEPRIS. It offers CDMO services for generic APIs & NCEs, intermediates & key building blocks.Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Aarti Industries Company Banner

05

arrow
Biotech Digital Meet
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content

Osimertinib Mesylate

About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...

Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development Zone, Shandong Province, Shandong Loncom has operational API pilot tests and production bases adhering to international standards. With 13 production lines dedicated to oral solid preparations, oral liquid preparations and API, it is actively expanding its preparation workshops for small-volume injections, soft capsules, eye drops, topical medicines and innovative drug R&D centres.
Shandong Loncom Pharmaceutical company banner

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

Osimertinib Mesylate

About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...

Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, driving progress in the pharmaceutical industry. Leveraging our extensive experience and world-class expertise, we deliver one of the most comprehensive API portfolios in the industry with over 350 Products portfolio. Additionally, we provide tailored CDMO services, harnessing our proficiency in diverse technologies to meet our partners' unique needs, ensuring flexibility and excellence in every project.
TAPI Company Banner

07

Biotech Digital Meet
Not Confirmed
arrow
arrow
Biotech Digital Meet
Not Confirmed

Osimertinib Mesylate

About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates.
blank

08

Biotech Digital Meet
Not Confirmed
arrow
arrow
Biotech Digital Meet
Not Confirmed

Osimertinib

About the Company : Bulat Pharmaceutical is a fast growing pharmaceutical company, founded in the year 2017, Bulat Pharmaceutical is engaged in the manufacturing and sales of high quality APIs and Int...

blank

09

Biotech Digital Meet
Not Confirmed
arrow
arrow
Biotech Digital Meet
Not Confirmed

AZD-9291 mesylate

About the Company : Haoyuan Chemexpress Co., Ltd., located in Shanghai Zhangjiang Biomedical Base, is a high-tech company specializing in customized chemical synthesis and R&D of pharmaceutical interm...

Haoyuan Chemexpress Co., Ltd., located in Shanghai Zhangjiang Biomedical Base, is a high-tech company specializing in customized chemical synthesis and R&D of pharmaceutical intermediates and new drugs. The company is mainly engaged in customized synthesis of complex small molecule frameworks and pharmaceutical intermediates, and independent R&D of innovative new drugs; and provides services of production technology improvement and consigned new drug development for pharmaceutical enterprises. Haoyuan Chemexpress is committed to researching and developing APIs and pharmaceutical intermediates with high synthesis technology barriers and difficulties and high added value, and also focuses on the synthesis of chiral compounds.
blank

10

Hetero Drugs

India
Biotech Digital Meet
Not Confirmed
arrow

Hetero Drugs

India
arrow
Biotech Digital Meet
Not Confirmed

Osimertinib

About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...

Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs. Hetero is building on the strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialization.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"OSIMERTINIB MESYLATE","year":"2021","qtr":"Q2","strtotime":1619116200,"product":"OSIMERTINIB MESYLATE (GROUP:A) (TAX INV NO:1905215006 DT:16.04.2021","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"ZAGREB","customer":"A2B EXPRESS LIGISTIKA ","customerCountry":"CROATIA","quantity":"0.05","actualQuantity":"0.05","unit":"KGS","unitRateFc":"33837.8","totalValueFC":"1637.4","currency":"USD","unitRateINR":2438010,"date":"23-Apr-2021","totalValueINR":"121900.5","totalValueInUsd":"1637.4","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"1307401","productDescription":"API","marketType":"REGULATED MARKET","country":"CROATIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1629225000,"product":"OSIMERTINIB MESYLATE (GROUP:A) (TAX INV","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"ESKAYEF PHARMACEUTICAL LIMITED","customerCountry":"BANGLADESH","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"25000","totalValueFC":"2400","currency":"USD","unitRateINR":1780000,"date":"18-Aug-2021","totalValueINR":"178000","totalValueInUsd":"2400","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"3948962","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1668018600,"product":"OSIMERTINIB MESYLATE, B.NO.2204005231, M","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"22000","totalValueFC":"33193.4","currency":"USD","unitRateINR":1806000,"date":"10-Nov-2022","totalValueINR":"2709000","totalValueInUsd":"33193.4","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"5364234","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669746600,"product":"OSIMERTINIB MESYLATE, B.NO. 2204006009,","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"MONTEVIDEO -","customer":"TO THE ORDER OF","customerCountry":"URUGUAY","quantity":"0.90","actualQuantity":"0.9","unit":"KGS","unitRateFc":"22000","totalValueFC":"19053.4","currency":"USD","unitRateINR":1727777.7777777778,"date":"30-Nov-2022","totalValueINR":"1555000","totalValueInUsd":"19053.4","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"5815747","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"URUGAY","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1674585000,"product":"OSIMERTINIB MESYLATE OSY3 (YS)","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PVT LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"A5 METAL SANAYI VE TICARET ANONIM","customerCountry":"TURKEY","quantity":"0.60","actualQuantity":"0.6","unit":"KGS","unitRateFc":"20755","totalValueFC":"12267.7","currency":"USD","unitRateINR":1671666.6666666667,"date":"25-Jan-2023","totalValueINR":"1003000","totalValueInUsd":"12267.7","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"7252732","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1674585000,"product":"OSIMERTINIB MESYLATE OSY3 (YS)","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PVT LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"A5 METAL SANAYI VE TICARET ANONIM","customerCountry":"TURKEY","quantity":"1.20","actualQuantity":"1.2","unit":"KGS","unitRateFc":"18430","totalValueFC":"21783.4","currency":"USD","unitRateINR":1484166.6666666667,"date":"25-Jan-2023","totalValueINR":"1781000","totalValueInUsd":"21783.4","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"7252461","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1678905000,"product":"OSIMERTINIB MESYLATE IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR CONTA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"TO THE ORDER M\/S AMEDART LLC#","customerCountry":"RUSSIA","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"17500","totalValueFC":"3173.2","currency":"USD","unitRateINR":1305000,"date":"16-Mar-2023","totalValueINR":"261000","totalValueInUsd":"3173.2","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"8520885","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR CONTA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1685557800,"product":"OSIMERTINIB MESYLATE, B.NO. 2204005231,","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF","customerCountry":"UNITED ARAB EMIRATES","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"22000","totalValueFC":"87303.2","currency":"USD","unitRateINR":1794000.0487500001,"date":"01-Jun-2023","totalValueINR":"7176000.195","totalValueInUsd":"87303.2","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691519400,"product":"OSIMERTINIB MESYLATE","address":"NA","city":"VADODARA","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"Z TO ORDER AND NA","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.90","actualQuantity":"1.9","unit":"KGS","unitRateFc":"18000","totalValueFC":"33746","currency":"USD","unitRateINR":1471261.9452631581,"date":"09-Aug-2023","totalValueINR":"2795397.696","totalValueInUsd":"33746","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"NA, VADODARA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1698949800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS-(API): OSIMERTINIB MESYLATE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"21000","totalValueFC":"2077.6","currency":"USD","unitRateINR":1730000,"date":"03-Nov-2023","totalValueINR":"173000","totalValueInUsd":"2077.6","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"5114614","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1698949800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS-(API): OSIMERTINIB MESYLATE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"21000","totalValueFC":"20775.6","currency":"USD","unitRateINR":1730000,"date":"03-Nov-2023","totalValueINR":"1730000","totalValueInUsd":"20775.6","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"5114420","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1704997800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS - (PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) PRODUCT - OSIMERTINIB MESYLATE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"MONTEVIDEO -","customer":"TO","customerCountry":"URUGUAY","quantity":"0.40","actualQuantity":"0.4","unit":"KGS","unitRateFc":"22000","totalValueFC":"8371.1","currency":"USD","unitRateINR":1739344.125,"date":"12-Jan-2024","totalValueINR":"695737.65","totalValueInUsd":"8371.1","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"6705898","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"URUGAY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705429800,"product":"RAW MATERIAL FOR USE IN PHARMACEUTICAL INDUSTRY : OSIMERTINIB MESYLATE IHS","address":"A 401 NEELKANTH AVENUE,OPP SEEMA H","city":"AHMEDABAD,GUJARAT","supplier":"GONANE PHARMA","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"HSBC BANK","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"13000","totalValueFC":"2368.4","currency":"USD","unitRateINR":984225.05000000005,"date":"17-Jan-2024","totalValueINR":"196845.01","totalValueInUsd":"2368.4","indian_port":"Ahmedabad Air","hs_no":"29242190","bill_no":"6808026","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"A 401 NEELKANTH AVENUE,OPP SEEMA H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705861800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS -(API) (PHARMACEUTICALS RAW MATERIAL FOR PHARMA)PRODUCT- OSIMERTINIB MESYLATE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"BUDAPEST,","customer":"TO THE ORDER OF","customerCountry":"HUNGARY","quantity":"5.50","actualQuantity":"5.5","unit":"KGS","unitRateFc":"10000","totalValueFC":"54363.8","currency":"USD","unitRateINR":821502.78727272723,"date":"22-Jan-2024","totalValueINR":"4518265.33","totalValueInUsd":"54363.8","indian_port":"Ahmedabad Air","hs_no":"29335990","bill_no":"6937264","productDescription":"API","marketType":"REGULATED MARKET","country":"HUNGARY","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1723746600,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) OSIMERTINIB MESYLATE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TO THE ORDER OF","customerCountry":"TURKEY","quantity":"0.56","actualQuantity":"0.555","unit":"KGS","unitRateFc":"7000","totalValueFC":"3718.9","currency":"USD","unitRateINR":562047.98198198189,"date":"16-Aug-2024","totalValueINR":"311936.63","totalValueInUsd":"3718.9","indian_port":"Ahmedabad Air","hs_no":"29335990","bill_no":"3256323","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""}]
23-Apr-2021
16-Aug-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Orpathys is an MET tyrosine kinase inhibitor. Tagrisso is a third-generation, irreversible EGFR TKI. These are being evaluated in combination with EGFR mutation-positive non-small cell lung cancer.


Lead Product(s): Savolitinib,Osimertinib Mesylate

Therapeutic Area: Oncology Brand Name: Orpathys

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 01, 2025

blank

01

Hutchmed

Hong Kong
arrow
Biotech Digital Meet
Not Confirmed

Hutchmed

Hong Kong
arrow
Biotech Digital Meet
Not Confirmed

Details : Orpathys is an MET tyrosine kinase inhibitor. Tagrisso is a third-generation, irreversible EGFR TKI. These are being evaluated in combination with EGFR mutation-positive non-small cell lung cancer.

Product Name : Orpathys

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 01, 2025

blank

Details:

Orpathys (savolitinib) is an oral, potent and highly selective MET tyrosine kinase inhibitor. It is investigated in combination with osimertinib for EGFR-mutated NSCLC.


Lead Product(s): Savolitinib,Osimertinib Mesylate

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 11, 2024

blank

02

Hutchmed

Hong Kong
arrow
Biotech Digital Meet
Not Confirmed

Hutchmed

Hong Kong
arrow
Biotech Digital Meet
Not Confirmed

Details : Orpathys (savolitinib) is an oral, potent and highly selective MET tyrosine kinase inhibitor. It is investigated in combination with osimertinib for EGFR-mutated NSCLC.

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Not Applicable

December 11, 2024

blank

Details:

Tagrisso (osimertinib) is being evaluated in the mid-stage clinical trial studies in combination with Orpathys (savolitinib) for EFGR-mutated non-small cell lung cancer.


Lead Product(s): Osimertinib Mesylate,Savolitinib

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 16, 2024

blank

03

Hutchmed

Hong Kong
arrow
Biotech Digital Meet
Not Confirmed

Hutchmed

Hong Kong
arrow
Biotech Digital Meet
Not Confirmed

Details : Tagrisso (osimertinib) is being evaluated in the mid-stage clinical trial studies in combination with Orpathys (savolitinib) for EFGR-mutated non-small cell lung cancer.

Product Name : Tagrisso

Product Type : Small molecule

Upfront Cash : Not Applicable

October 16, 2024

blank

Details:

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is indicated for treatment of patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.


Lead Product(s): Osimertinib Mesylate

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 26, 2024

blank

04

AstraZeneca

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

AstraZeneca

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is indicated for treatment of patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.

Product Name : Tagrisso

Product Type : Small molecule

Upfront Cash : Not Applicable

September 26, 2024

blank

Details:

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.


Lead Product(s): Osimertinib Mesylate

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 06, 2024

blank

05

AstraZeneca

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

AstraZeneca

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.

Product Name : Tagrisso

Product Type : Small molecule

Upfront Cash : Not Applicable

July 06, 2024

blank

Details:

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.


Lead Product(s): Osimertinib Mesylate

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 10, 2024

blank

06

AstraZeneca

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

AstraZeneca

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.

Product Name : Tagrisso

Product Type : Small molecule

Upfront Cash : Not Applicable

June 10, 2024

blank

Details:

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.


Lead Product(s): Osimertinib Mesylate

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2024

blank

07

AstraZeneca

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

AstraZeneca

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.

Product Name : Tagrisso

Product Type : Small molecule

Upfront Cash : Not Applicable

June 02, 2024

blank

Details:

Tagrisso (osimertinib mesylate) is a third-generation, irreversible EGFR-TKI, small molecule drug candidate which is being evaluated for the treatment of EGFR-mutated advanced lung cancer.


Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 21, 2024

blank

08

AstraZeneca

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

AstraZeneca

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

Details : Tagrisso (osimertinib mesylate) is a third-generation, irreversible EGFR-TKI, small molecule drug candidate which is being evaluated for the treatment of EGFR-mutated advanced lung cancer.

Product Name : Tagrisso

Product Type : Small molecule

Upfront Cash : Not Applicable

March 21, 2024

blank

Details:

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.


Lead Product(s): Osimertinib Mesylate

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 19, 2024

blank

09

AstraZeneca

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

AstraZeneca

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.

Product Name : Tagrisso

Product Type : Small molecule

Upfront Cash : Not Applicable

February 19, 2024

blank

Details:

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI which is approved in combination with chemotherapy for the treatment of EGFR-mutated advanced non-small cell lung cancer.


Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 16, 2024

blank

10

AstraZeneca

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

AstraZeneca

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI which is approved in combination with chemotherapy for the treatment of EGFR-mutated advanced non-small cell lung cancer.

Product Name : Tagrisso

Product Type : Small molecule

Upfront Cash : Not Applicable

February 16, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

ASTRAZENECA

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

Brand Name : TAGRISSO

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 40MG BASE

Approval Date : 2015-11-13

Application Number : 208065

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

02

ASTRAZENECA

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

Brand Name : TAGRISSO

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 80MG BASE

Approval Date : 2015-11-13

Application Number : 208065

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

03

Biotech Digital Meet
Not Confirmed
arrow
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

Brand Name : OSIMERTINIB MESYLATE

Dosage Form : TABLET;ORAL

Dosage Strength : 40MG

Approval Date :

Application Number : 214263

RX/OTC/DISCN :

RLD :

TE Code :

blank

04

Biotech Digital Meet
Not Confirmed
arrow
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

Brand Name : OSIMERTINIB MESYLATE

Dosage Form : TABLET;ORAL

Dosage Strength : 80MG

Approval Date :

Application Number : 214263

RX/OTC/DISCN :

RLD :

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

AstraZeneca AB

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

AstraZeneca AB

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

osimertinibmesilat

Brand Name : TAGRISSO

Dosage Form : FILM COATED PILL

Dosage Strength : 80 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

02

AstraZeneca AB

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

AstraZeneca AB

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

osimertinibmesilat

Brand Name : TAGRISSO

Dosage Form : FILM COATED PILL

Dosage Strength : 40 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

03

AstraZeneca AB (2)

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

AstraZeneca AB (2)

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

AZD-9291 mesylate

Brand Name : Tagrisso

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 40 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

04

AstraZeneca AB (2)

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

AstraZeneca AB (2)

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

AZD-9291 mesylate

Brand Name : Tagrisso

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 80 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

05

AstraZeneca AG

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

AstraZeneca AG

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

Osimertinibum

Brand Name : Tagrisso

Dosage Form : Tabl

Dosage Strength : 40mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

06

AstraZeneca AG

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

AstraZeneca AG

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

Osimertinibum

Brand Name : Tagrisso

Dosage Form : Tabl

Dosage Strength : 80mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

read-more
read-more

01

ASTRAZENECA CANADA INC

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

ASTRAZENECA CANADA INC

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB (OSIMERTINIB MESYLATE)

Brand Name : TAGRISSO

Dosage Form : TABLET

Dosage Strength : 80MG

Packaging : 30

Approval Date :

Application Number : 2456222

Regulatory Info :

Registration Country : Canada

blank

02

ASTRAZENECA CANADA INC

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

ASTRAZENECA CANADA INC

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB (OSIMERTINIB MESYLATE)

Brand Name : TAGRISSO

Dosage Form : TABLET

Dosage Strength : 40MG

Packaging : 30

Approval Date :

Application Number : 2456214

Regulatory Info :

Registration Country : Canada

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Australia

read-more
read-more

01

AstraZeneca Pty Ltd

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

AstraZeneca Pty Ltd

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

osimertinib

Brand Name : Tagrisso

Dosage Form :

Dosage Strength :

Packaging : 30

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

02

AstraZeneca Pty Ltd

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

AstraZeneca Pty Ltd

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

osimertinib

Brand Name : Tagrisso

Dosage Form :

Dosage Strength :

Packaging : 30

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

03

AstraZeneca Pty Ltd

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

AstraZeneca Pty Ltd

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

osimertinib

Brand Name : Tagrisso

Dosage Form :

Dosage Strength :

Packaging : 30

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

04

AstraZeneca Pty Ltd

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

AstraZeneca Pty Ltd

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

osimertinib

Brand Name : Tagrisso

Dosage Form :

Dosage Strength :

Packaging : 30

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

05

AstraZeneca Pty Ltd

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

AstraZeneca Pty Ltd

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

osimertinib

Brand Name : Tagrisso

Dosage Form :

Dosage Strength :

Packaging : 30

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

06

AstraZeneca Pty Ltd

United Kingdom
Biotech Digital Meet
Not Confirmed
arrow

AstraZeneca Pty Ltd

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

osimertinib

Brand Name : Tagrisso

Dosage Form :

Dosage Strength :

Packaging : 30

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content

Regulatory Info :

Registration Country : Hungary

Osimertinib Mesylate

Brand Name :

Dosage Form : Tablet

Dosage Strength : 40MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Hungary

Egis Pharmaceuticals

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content

Packaging :

Regulatory Info :

Osimertinib Mesylate

Dosage : Tablet

Dosage Strength : 40MG

Brand Name :

Approval Date :

Application Number :

Registration Country : Hungary

Egis Pharmaceuticals

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content

Regulatory Info :

Registration Country : Hungary

Osimertinib Mesylate

Brand Name :

Dosage Form : Tablet

Dosage Strength : 80MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Hungary

Egis Pharmaceuticals

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content

Packaging :

Regulatory Info :

Osimertinib Mesylate

Dosage : Tablet

Dosage Strength : 80MG

Brand Name :

Approval Date :

Application Number :

Registration Country : Hungary

Egis Pharmaceuticals

03

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Osimertinib Mesylate

Brand Name : Mertisso

Dosage Form : Film Coated Tablet

Dosage Strength : 40MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

NanoAlvand

03

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Packaging :

Regulatory Info :

Osimertinib Mesylate

Dosage : Film Coated Tablet

Dosage Strength : 40MG

Brand Name : Mertisso

Approval Date :

Application Number :

Registration Country : Iran

NanoAlvand

04

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Osimertinib Mesylate

Brand Name : Mertisso

Dosage Form : Film Coated Tablet

Dosage Strength : 80MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

NanoAlvand

04

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Packaging :

Regulatory Info :

Osimertinib Mesylate

Dosage : Film Coated Tablet

Dosage Strength : 80MG

Brand Name : Mertisso

Approval Date :

Application Number :

Registration Country : Iran

NanoAlvand

05

Pluviaendo

Turkey
Biotech Digital Meet
Not Confirmed
arrow

Pluviaendo

Turkey
arrow
Biotech Digital Meet
Not Confirmed

Osimertinib Mesylate

Brand Name :

Dosage Form : Tablet

Dosage Strength : 40MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Turkey

blank

05

Pluviaendo

Turkey
Biotech Digital Meet
Not Confirmed
arrow

Pluviaendo

Turkey
arrow
Biotech Digital Meet
Not Confirmed

Osimertinib Mesylate

Dosage : Tablet

Dosage Strength : 40MG

Brand Name :

Approval Date :

Application Number :

Registration Country : Turkey

blank

06

Pluviaendo

Turkey
Biotech Digital Meet
Not Confirmed
arrow

Pluviaendo

Turkey
arrow
Biotech Digital Meet
Not Confirmed

Osimertinib Mesylate

Brand Name :

Dosage Form : Tablet

Dosage Strength : 80MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Turkey

blank

06

Pluviaendo

Turkey
Biotech Digital Meet
Not Confirmed
arrow

Pluviaendo

Turkey
arrow
Biotech Digital Meet
Not Confirmed

Osimertinib Mesylate

Dosage : Tablet

Dosage Strength : 80MG

Brand Name :

Approval Date :

Application Number :

Registration Country : Turkey

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
PharmaCompass
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

US Patent Number : 10183020

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 208065

Patent Use Code : U-3823

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-01-02

blank

02

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

US Patent Number : 8946235

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 208065

Patent Use Code : U-1777

Delist Requested :

Patent Use Description : TREATMENT OF PATIENTS ...

Patent Expiration Date : 2032-08-08

blank

03

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

US Patent Number : 8946235

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 208065

Patent Use Code : U-4010

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-08-08

blank

04

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

US Patent Number : 11524951

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 208065

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-07-25

blank

05

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

US Patent Number : 9732058

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 208065

Patent Use Code : U-2289

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-07-25

blank

06

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

US Patent Number : 9732058

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 208065

Patent Use Code : U-4010

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-07-25

blank

07

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

US Patent Number : 10183020

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 208065

Patent Use Code : U-3823

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-01-02

blank

08

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

US Patent Number : 8946235

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 208065

Patent Use Code : U-2289

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-08-08

blank

09

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

US Patent Number : 11524951

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 208065

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-07-25

blank

10

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

US Patent Number : 9732058

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 208065

Patent Use Code : U-4010

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-07-25

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

read-more
read-more

01

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

Exclusivity Code : ODE-176

Exclusivity Expiration Date : 2025-04-18

Application Number : 208065

Product Number : 1

Exclusivity Details :

blank

02

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

Exclusivity Code : ODE-337

Exclusivity Expiration Date : 2027-12-18

Application Number : 208065

Product Number : 1

Exclusivity Details :

blank

03

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

Exclusivity Code : I-941

Exclusivity Expiration Date : 2027-02-16

Application Number : 208065

Product Number : 1

Exclusivity Details :

blank

04

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

Exclusivity Code : I-952

Exclusivity Expiration Date : 2027-09-25

Application Number : 208065

Product Number : 1

Exclusivity Details :

blank

05

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

Exclusivity Code : ODE-176

Exclusivity Expiration Date : 2025-04-18

Application Number : 208065

Product Number : 2

Exclusivity Details :

blank

06

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

Exclusivity Code : ODE-337

Exclusivity Expiration Date : 2027-12-18

Application Number : 208065

Product Number : 2

Exclusivity Details :

blank

07

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

Exclusivity Code : I-941

Exclusivity Expiration Date : 2027-02-16

Application Number : 208065

Product Number : 2

Exclusivity Details :

blank

08

arrow
Biotech Digital Meet
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

OSIMERTINIB MESYLATE

Exclusivity Code : I-952

Exclusivity Expiration Date : 2027-09-25

Application Number : 208065

Product Number : 2

Exclusivity Details :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Health Canada Patents

read-more
read-more

01

arrow
Biotech Digital Meet
Not Confirmed

AstraZeneca Canada Inc.

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

Osimertinib Mesylate

Brand Name : TAGRISSO

Patent Number : 2843109

Filing Date : 2012-07-25

Strength per Unit : 40mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-07-25

Date Granted : 2015-06-16

blank

02

arrow
Biotech Digital Meet
Not Confirmed

AstraZeneca Canada Inc.

United Kingdom
arrow
Biotech Digital Meet
Not Confirmed

Osimertinib Mesylate

Brand Name : TAGRISSO

Patent Number : 2843109

Filing Date : 2012-07-25

Strength per Unit : 80mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-07-25

Date Granted : 2015-06-16

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 1421373-66-1 / Osimertinib Mesylate API manufacturers, exporters & distributors?

Osimertinib Mesylate manufacturers, exporters & distributors 1

71

PharmaCompass offers a list of Osimertinib Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Osimertinib Mesylate manufacturer or Osimertinib Mesylate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Osimertinib Mesylate manufacturer or Osimertinib Mesylate supplier.

PharmaCompass also assists you with knowing the Osimertinib Mesylate API Price utilized in the formulation of products. Osimertinib Mesylate API Price is not always fixed or binding as the Osimertinib Mesylate Price is obtained through a variety of data sources. The Osimertinib Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Osimertinib Mesylate

Synonyms

1421373-66-1, Azd-9291 mesylate, Azd9291 mesylate, Azd-9291 (mesylate), Mereletinib mesylate, Tagrisso

Cas Number

1421373-66-1

Unique Ingredient Identifier (UNII)

RDL94R2A16

About Osimertinib Mesylate

Osimertinib Mesylate is the mesylate salt form of osimertinib, a third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.

Osimertinib Manufacturers

A Osimertinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Osimertinib, including repackagers and relabelers. The FDA regulates Osimertinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Osimertinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Osimertinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Osimertinib Suppliers

A Osimertinib supplier is an individual or a company that provides Osimertinib active pharmaceutical ingredient (API) or Osimertinib finished formulations upon request. The Osimertinib suppliers may include Osimertinib API manufacturers, exporters, distributors and traders.

click here to find a list of Osimertinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Osimertinib USDMF

A Osimertinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Osimertinib active pharmaceutical ingredient (API) in detail. Different forms of Osimertinib DMFs exist exist since differing nations have different regulations, such as Osimertinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Osimertinib DMF submitted to regulatory agencies in the US is known as a USDMF. Osimertinib USDMF includes data on Osimertinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Osimertinib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Osimertinib suppliers with USDMF on PharmaCompass.

Osimertinib KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Osimertinib Drug Master File in Korea (Osimertinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Osimertinib. The MFDS reviews the Osimertinib KDMF as part of the drug registration process and uses the information provided in the Osimertinib KDMF to evaluate the safety and efficacy of the drug.

After submitting a Osimertinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Osimertinib API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Osimertinib suppliers with KDMF on PharmaCompass.

Osimertinib WC

A Osimertinib written confirmation (Osimertinib WC) is an official document issued by a regulatory agency to a Osimertinib manufacturer, verifying that the manufacturing facility of a Osimertinib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Osimertinib APIs or Osimertinib finished pharmaceutical products to another nation, regulatory agencies frequently require a Osimertinib WC (written confirmation) as part of the regulatory process.

click here to find a list of Osimertinib suppliers with Written Confirmation (WC) on PharmaCompass.

Osimertinib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Osimertinib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Osimertinib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Osimertinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Osimertinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Osimertinib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Osimertinib suppliers with NDC on PharmaCompass.

Osimertinib GMP

Osimertinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Osimertinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Osimertinib GMP manufacturer or Osimertinib GMP API supplier for your needs.

Osimertinib CoA

A Osimertinib CoA (Certificate of Analysis) is a formal document that attests to Osimertinib's compliance with Osimertinib specifications and serves as a tool for batch-level quality control.

Osimertinib CoA mostly includes findings from lab analyses of a specific batch. For each Osimertinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Osimertinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Osimertinib EP), Osimertinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Osimertinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty